SUMMARY A therapeutic trial with verapamil, a calcium-antagonist drug, was performed in 12 patients admitted to our coronary care unit because offrequent daily attacks ofangina at rest attributed to coronary vasospasm. After a 48-hour run-in period, oral verapamil 480 mg/day and placebo were administered alternately during 4 randomised 48-hour periods. Transient ischaemic attacks with ST segment elevation or depression, with or without pain, were documented by continuous electrocardiographic monitoring. The number of attacks during the run-in and 2 placebo periods were 128, 123, and 130, respectively, and 31 and 23 during the 2 treatment periods (P < 0.006 and P < 0.003). This drug therefore appears to be effective in the management of patients with frequent attacks of angina at rest.
Although various forms ol medical and surgical treatment have been proposed for the management of unstable angina at rest, the results are inconclusive (Cairns et al., 1976) and often conflicting (Conti et al., 1973; Bertolasi et al., 1974; Hultgren, 1976; Selzer et al., 1976; Clark et al., 1977) . This may be because the patients are selected on purely clinical criteria, rather than on criteria based on the pathogenetic mechanisms responsible for the onset of the anginal attacks; this method of selection leads to an inhomogeneous group of patients and treatment that is not rational. Rational therapy depends on recognition of the causes of the anginal attacks rather than on the clinical picture alone, which though it has prognostic significance has no clear pathogenetic implications.
Recent studies indicate that in patients with angina at rest, characterised by ST segment elevation or depression, the onset of the attacks cannot be attributed to an increase in the haemodynamic determinants of myocardial oxygen consumption (Guazzi et al., 1971 (Guazzi et al., , 1975b Maseri et al., 1975a, b) . In these patients myocardial scintigraphic studies have shown a massive transmural reduction of myocardial tracer uptake during the attacks, associated with ST segment elevation Parodi et al., 1978) or a diffuse or ill-defined reduction of tracer uptake during episodes of angina at rest with ST segment depression . This reduction of myocardial perfusion appears to be related to either:
Received for publication 14 February 1978 (1) severe vasospasm of a major coronary branch, when the perfusion deficit is transmural and the ST segment is elevated, or (2) less severe spasm or a spasm of a small branch or spasm in the presence of collaterals, when reduction of perfusion is not transmural and the ST segment is depressed (Marzilli et al., 1977; Maseri et al., 1977b; Parodi et al., 1977) .
Beta-blockers and coronary bypass surgery, which are the most commonly adopted therapeutic approaches (Cairns et al., 1976) , may not be the rational treatment in those patients with proven vasospastic angina with the clinical characteristic of 'unstable' angina at rest or of 'crescendo' angina.
In preliminary clinical trials we had the impression that verapamill, a calcium-antagonist with relaxing properties on large coronary arteries (Golenhofen and Lammel, 1972; Haeusler, 1972) , was effective in reducing the number of anginal attacks in those patients. Hence we decided to undertake a double-blind cross-over study with this drug on patients having continuous electrocardiographic monitoring in a coronary care unit (CCU).
Subjects and methods

PATIENTS
We studied 12 patients (34 to 70 years old, average 54 years) admitted to our CCU because ofrecurrent, frequent daily episodes of angina at rest, which began from 3 months to 10 days before admission. We excluded from the study patients with anginal episodes of long duration (more than 10 to 15 minutes).
The main physical, clinical, and electrocardiographic characteristics of the patients, the results of coronary angiography, and of thallium-201 myocardial scintigraphic studies are reported in Table 1 . Two had had a documented old myocardial infarction, 7 and 25 months before admission. None had a history or clinical signs of congestive heart failure on admission. The electrocardiographic abnormalities during the anginal attacks were ST segment elevation in 6 patients, ST segment depression in 4, and alternate episodes of ST segment elevation and depression in the same leads in 2. Seven patients had in addition asymptomatic episodes of ST segment changes similar to those accompanied by pain. Coronary arteriography was performed by the Judkins technique (1968) in all the 8 patients in whom thallium-201 could be injected at the beginning of an ischaemic episode. In 3 patients no direct evidence of a sudden reduction of myocardial blood supply was obtained, as the appropriate studies could not be performed because of failure of the equipment or lack of isotope. However, these patients had no history of effort angina, and repeated measurements of heart rate and systemic blood pressure at the very beginning of the ST segment changes or before the onset of pain failed to show any consistent change relative to control state. No haemodynamic change was observed at the onset of pain in the 3 patients (cases 9, 10, and 11) in whom left ventricular pressure was continuously monitored (Chierchia et al., 1977 During the whole period of the trial the paradays medical CCU personnel were instructed to record Treatment A2: verapamil (80 mg) 1 tablet every 4 the monitored lead during each episode of ST hours for 2 days (480 mg/24 h) segment change and, whenever possible, a 12-lead Treatment B2: placebo 1 tablet every 4 hours for 2 electrocardiogram. Blood pressure was recorded days.
every 4 hours and heart rate every 2 hours during The two sequences of treatments Al, B1, A2, B2 or periods free of ischaemic episodes and whenever The patients were informed that neither the rationale nor the effectiveness of treatment of this syndrome were yet established and that, given the large spontaneous variability in the frequency of symptoms, the choice of a drug for long-term treatment would require objective demonstration of its efficacy. All gave their written consent to the trial.
A statistical evaluation of the significance of the results was carried out by the Wilcoxon matchedpair signed-rank test (Snedecor and Cochran, 1964 
Results
During the trial symptomatic and asymptomatic episodes of ST segment elevation or depression were recorded and were pooled in the statistical analysis. For each patient the total number of ischaemic attacks during the control, treatment, and placebo periods is reported in Table 2 . Detailed results of the trial in the 12 patients are presented in Fig. 1  and 2 .
No episodes were observed during both periods of treatment in 2 patients and during 1 of the 2 periods in 4. All the others except case 12 consistently showed an obvious reduction in the number of episodes.
For the group as a whole, the number of episodes during the 48-hour run-in period was not statistically different from that during the placebo periods (128 versus 123 and 130). By contrast, during each period of verapamil treatment, a highly significant reduction in the number of episodes was observed (31 and 23, P < 0006 and P < 0 003). The reduc- Fig. 1 (Crochet et al., 1975) ) are a relatively small number. In fact, patients with 'variant' angina, for whomvasospasmcanbecon- sidered a 'proven hypothesis' (Meller et al., 1976) , are found to be a sizeable fraction of those with angina pectoris at rest if appropriately searched for (Maseri et al., 1977a, b) . In addition, vasospasm has also been shown to be a cause of angina at rest with ST segment depression in patients with a variable degree of coronary atherosclerosis (Marzilli et al., 1977; Maseri et al., 1977a) . Finally, it has been shown by continuous ambulatory electrocardiographic monitoring that the majority of patients with 'stable' angina have ischaemic episodes at rest or at considerably lower work loads than can be achieved during an exercise test; it was suggested that in these patients functional impairment of coronary blood supply capable of causing these anginal attacks may be superimposed (Schang and Pepine, 1977) . The evaluation of the effectiveness of drugs on vasospastic angina is thus of practical interest. There were several reasons for believing that anginal attacks at rest in our group of patients were not caused by an increase of myocardial demand: (1) Five patients had no history of exertional angina; of these 1 had a normal electrocardiographic stress test and2 developed electrocardiographic signs of ischaemia only at high work loads; (2) in 3 patients continuous haemodynamic monitoring showed that no consistent increase of heart work preceded the onset of the ischaemic episodes; (3) in all patients systematic measurements of blood pressure and heart rate during asymptomatic electrocardiographic ischaemic episodes or at the onset of ST segment changes showed no consistent increase relative to the control periods.
Direct evidence for a vasospastic origin of the attacks was obtained in 9 patients: by both angiography and by myocardial scintigraphy in 5, by myocardial scintigraphy alone in 3, and by angiography alone in 1. In the other 3 patients there was no history of exertional angina, and no consistent increase in heart rate or blood pressure at the onset of anginal attacks. Two had typical 'variant' angina. Thus, all these patients appear to have a common mechanism responsible for the onset of their anginal attacks at rest, which cannot be attributed to an increase of myocardial metabolic demand beyond their coronary reserve. Though we cannot exclude other so far unidentified mechanisms, it is reasonable to infer that their attacks were caused by coronary vasospasm, in spite of the difference in the time of onset of angina, the extent of coronary atherosclerosis, and type of electrocardiographic ST segment change during ischaemia.
The study was carried out in the CCU both because of the severity of the patients' symptoms and because in this environment treatment could be closely supervised and an objective unbiased record obtained of the response to treatment. We selected patients who were having several anginal episodes per day and studied 2 treatment periods alternating with 2 placebo periods, with the aim of comparing the extent and the consistency of the response of the individual patients with that of the group as a whole. We selected 48-hour periods, because of the 2 to 3 hour half-life in blood of the drug after its oral administration (Schomerus et al., 1976) , and because of possible carry-over effects of the drug. Longer periods of treatment were not adopted in view of the frequent spontaneous waxing and waning of the disease. We chose a higher than usual dose of the drug in order to overcome possible differences in absorption and to be reasonably certain that an adequate blood level was attained.
A non-parametric test was selected for the statistical evaluation of the results because of the possible lack of homogeneity of response among patients, as it should tend to reduce the influence of a few exceptional responders.
PREVENTION OF ISCHAEMIC EPISODES
A study of Fig. 1 and 2 shows that verapamil appears to be consistently effective in reducing the number of ischaemic episodes in patients in whom angina was predominantly associated with ST segment elevation, in those with angina and ST segment depression, and in those with asymptomatic ST segment changes. The reduction was more obvious in the patients with frequent episodes during the placebo periods. We could not find an explanation for the inconsistent effects observed in case 12 but have previously observed in a trial of intravenous isosorbide dinitrate Distante et al., 1978) that in some patients it is not possible to prevent ischaemic attacks completely, probably because of the very acute phase of their disease.
In the group as a whole, the reduction in number of ischaemic episodes during verapamil treatment was highly significant. Therefore, this drug seems to have a potent effect in preventing attacks of vasospastic angina. Because of the design of our trial (randomised, short-term, cross-over), it is not possible to compare our results with those obtained in other trials with less sophisticated experimental designs (Papazoglov, 1971; Guazzi et al., 1975a (Miller et al., 1973; Gaasch et al., 1974; Heng et al., 1976) and of other surgical procedures such as cardiac denervation or autotransplantation which have been performed in selected patients with proven coronary vasospasm (Clark et al., 1977) .
In conclusion, verapamil is an effective drug for the management of those patients in whom unstable angina at rest is not the result of an excessive increase of myocardial metabolic demand. 
